A Post Hoc Analysis of the CKD-FIX Study Analyzing the Association Between Metformin Usage and Estimated GFR Decline

Résumé fourni par la source

Chronic kidney disease (CKD) poses an increasing burden on global health, however there are few interventions available to manage the condition. It has been hypothesised that metformin, a commonly prescribed oral antidiabetic drug, may potentially be able to slow the progression of CKD.1 Metformin is the first line treatment for patients with type 2 diabetes mellitus (T2DM) due to its beneficial effects on blood glucose control and its tolerability.1 It primarily imparts its therapeutic actions through activation of adenosine monophosphate (AMP)-activated protein kinase, which subsequently inactivates the molecular target of rapamycin and its postulated downstream fibrogenic effects on the kidney.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.